drugset / Trial / NCT04272151
Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
This is a single arm study to evaluate the efficacy and safety of BCMA-targeted CAR-T cells therapy for patients with relapsed/refractory Multiple Myeloma.
Timeline
- Start
- 2019-12-01
- Primary completion
- 2023-12-31
- Completion
- 2024-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BCMA CAR-T cells | Cell therapy | — | Intravenous |